Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO)

• Published in: The Journal of dermatological treatment Vol. 35; no. 1; p. 2350227
• Main Authors: Pinter, Andreas, Eyerich, Kilian, Costanzo, Antonio, Garrelts, Alyssa, Schuster, Christopher, Mert, Can, Lampropoulou, Anastasia, Fotiou, Konstantinos, Maul, Julia-Tatjana, Papp, Kim A
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis Group 01-12-2024
• Subjects: Adult; Antibodies, Monoclonal, Humanized - therapeutic use; Biological Products - therapeutic use; biologics; Dermatologic Agents - therapeutic use; disease duration; Female; Humans; Interleukin-17 - antagonists & inhibitors; Male; Medicin och hälsovetenskap; Middle Aged; observational study; PASI response rates; Psoriasis; Psoriasis - drug therapy; real-world evidence; Severity of Illness Index; Time Factors; Treatment Outcome; PASI response rates; real-world evidence; Psoriasis; biologics; disease duration; observational study
• ISSN: 0954-6634; 1471-1753; 1471-1753
• DOI: 10.1080/09546634.2024.2350227

Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data from the Psoriasis Study of Health Outcomes (PSoHO), is to provide evidence if early intervention with biologics is associated with better treatment outcomes and if there is any difference among drug classes or individual biologics.
For this post-hoc analysis patients were categorised into two subgroups according to shorter (≤2 years) or longer (>2 years) disease duration. Analysis was performed on anti-interleukin (IL)-17A cohort vs other biologics cohort, anti-IL-17A vs other drug classes, and pairwise comparisons of ixekizumab vs individual biologics, provided that the statistical models converged. Analysis investigated the association of disease duration with the proportion of patients achieving 100% improvement in Psoriasis Area Severity Index score (PASI 100) at week 12. Adjusted comparative analyses, reported as odds ratio (OR), were performed using Frequentist Model Averaging (FMA) for each cohort or treatments within each subcategory of the subgroups.
At week 12, anti-IL-17A and other biologics cohorts displayed minimal differences in numerical response rate for PASI 100 with respect to disease duration. The anti-IL-17A cohort showed a higher numerical PASI 100 response rate compared to the other biologic cohort irrespective of disease duration (≤2 years: 36.7% vs 21.8%; >2 years: 35.8% vs 21.9%).
Overall, the results do not clearly indicate that treating patients early is critical in achieving optimal patient outcomes. Furthermore, patients treated with ixekizumab show numerically higher response rates relative to other individual biologics irrespective of disease duration.